Skip to main content Help with accessibility Skip to main navigation

Safety

Medicines Safety Assurance Tool

The Medicines Safety Assurance Tool (MSAT) is provided as a PDF document for reference. To request the spreadsheet solution of this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact mlcsu.medicines-safety@nhs.net.

The MSAT was developed to improve the management of medicines related risk to patients. It is intended to provide commissioners with a systematic way of identifying and analysing emerging medicines safety issues and engage with providers to reduce medicines related harm.

Transition of Commissioning Policies

On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.

Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.

NHS Cheshire and Merseyside Commissioning Policies

 

Documents

Date Added: 29 - Aug - 2023

Everyone involved in the support or care of people receiving clozapine is reminded of the importance of awareness and management of common side effects that may lead to life threatening conditions.

  • Constipation must be actively monitored and actively treated. Clozapine carries a serious risk of intestinal obstruction including faecal impaction and paralytic ileu.
  • Be cautious with signs or symptoms of a low white cell count. Clinical or haematological neutropenia or agranulocytosis can lead to an acute life threatening condition.
  • Monitor closely for tachycardia. Clozapine also carries a serious risk of myocarditis and cardiomyopathy particularly in the first two months of treatment.

NHS Cheshire and Merseyside APPROVED

Body System:
Date Added: 29 - Nov - 2017

Codeine is contraindicated in all children aged 0-18 years who undergo tonsillectomy or adenoidectomy (or both) for obstructive sleep apnoea. Codeine is restricted to children over 12 years of age and only if the benefit outweighs the risks.

Static

Body System: